Skip to content
Peptigraph home

GLOW

A pre-mixed blend of GHK-Cu, BPC-157 and TB-500. No controlled study has tested the blend itself; this hub covers the math and what each part has been studied for.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT (ingredients) evidence, 4 of 4
StatusNot FDA approved · unstudied blendProhibited by WADA (S0)Full legal history

Key facts

Class
Three-peptide blend
Pre-mixed blend
Also called
No common aliases
Vial sizes sold
50 mg, 70 mg
Community-reported sizes
Half-life
less than 30 min
IV and IM (single and repeated), rat, beagle dog · Frontiers in pharmacology 2022, PMID 36588717
FDA status
Not approved
unstudied blend
WADA
Prohibited (S0)
In and out of competition
Everything on GLOW

GLOW guides

What is in it

Amounts per vial vary by seller. No controlled study has tested the blend itself.

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies. GLOW itself has not been studied; grades come from its ingredients' studies.

GLOW: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Hair002Human observational evidence, 3 of 4GHK-Cu: Journal of cosmetic and laser therapy 2018, PMID 29482481
EyesNot in our ledgerNot in our ledger4Human RCT evidence, 4 of 4TB-500: Cornea 2015, PMID 25826322
Gut healthNot in our ledgerNot in our ledger5Animal evidence, 2 of 4GHK-Cu: Frontiers in pharmacology 2025, PMID 40672369
InflammationNot in our ledgerNot in our ledger7Human RCT evidence, 4 of 4TB-500: Microbial biotechnology 2021, PMID 34318587
Injury recoveryNot in our ledgerNot in our ledger26Human RCT evidence, 4 of 4TB-500: Annals of the New York Academy of Sciences 2010, PMID 20536470
Joint painNot in our ledgerNot in our ledger3Human observational evidence, 3 of 4BPC-157: Alternative therapies in health and medicine 2021, PMID 34324435
Muscle growthNot in our ledgerNot in our ledger0No graded study for this goal
Skin0013Human RCT evidence, 4 of 4TB-500: Microbial biotechnology 2021, PMID 34318587

Grades follow our evidence scale. Summarised studies come from our evidence files for GHK-Cu, BPC-157 and TB-500, each quote checked against the abstract or label.

Three components, three different evidence bases

GHK-Cu: a systematic review calls the human literature thin and fragmented, with mostly small trials of facial cosmetic creams.[38]

BPC-157: its systematic review reports no clinical safety data.[39]

TB-500: a doping-control paper describes a veterinary preparation containing a synthetic version of a thymosin beta-4 fragment.[40]

Has the trio been tested together

A PubMed search for BPC-157 and GHK-Cu together returned 7 records, none of which was classed as testing the pair.[41]

The one pair with a study found here is BPC-157 plus TB-500: a rat tendon study found no additional benefit from combining them.[42]

For GHK-Cu, FDA's compounding categories treat injectable routes differently from other routes.[43]

Sport

BPC-157 is named as an example under WADA's S0 class.[1]

WADA's S2.3 names TB-500 as an example of a thymosin-beta-4 derivative.[1]

Compared with

Common questions

Is GLOW FDA approved?

No. GLOW is not FDA approved for any use.

What is in GLOW?

GHK-Cu, BPC-157 and TB-500, pre-mixed in one vial. Amounts per vial vary by seller and are rarely verified.

Is GLOW banned in sport?

Yes. Prohibited by WADA (S0), so it is prohibited at all times for tested athletes.

How much water goes in a 50 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 25 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

Is the GLOW peptide blend studied?

Not as a trio: the cached search for two of the parts returned 7 records and none tested them together.[41]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: Not an approved product anywhere; see components (GHK-Cu, BPC-157, TB-500). Drugs@FDA (openFDA) search for the component GHK-Cu returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study.Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology · 2018PMID 29482481Accessed 2 Oct 2026
  4. 4Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.Cardiovascular research · 2025PMID 41229390Accessed 2 Oct 2026
  5. 5Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
  6. 6Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
  7. 7Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms.Frontiers in pharmacology · 2025PMID 40672369Accessed 2 Oct 2026
  8. 8Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.Microbial biotechnology · 2021PMID 34318587Accessed 2 Oct 2026
  9. 9The effect of thymosin treatment of venous ulcers.Annals of the New York Academy of Sciences · 2010PMID 20536470Accessed 2 Oct 2026
  10. 10Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.Alternative therapies in health and medicine · 2021PMID 34324435Accessed 2 Oct 2026
  11. 11PubMed search (GHK-Cu): ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) (431 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search (GHK-Cu): ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (humans[mh] OR patients[tiab] OR volunteers[tiab]) (150 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13PubMed search (GHK-Cu): ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (randomized[tiab] OR clinical trial[pt] OR split-face[tiab]) (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14PubMed search (GHK-Cu): ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (wound[tiab] OR hair[tiab] OR skin[tiab] OR wrinkle*[tiab]) (123 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search (GHK-Cu): ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16PubMed search (GHK-Cu): ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (rat[tiab] OR mice[tiab] OR rats[tiab] OR animal[tiab]) (80 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17PubMed search (GHK-Cu): ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (facial[tiab] OR cream[tiab] OR photodamage[tiab] OR volunteers[tiab] OR women[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18PubMed search (GHK-Cu): ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (hair[tiab] OR alopecia[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  19. 19PubMed search (GHK-Cu): ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (38 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  20. 20PubMed search (BPC-157): "BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab] (230 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  21. 21PubMed search (BPC-157): ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  22. 22PubMed search (BPC-157): "BPC-157"[tiab] AND humans[mh] (52 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  23. 23PubMed search (BPC-157): ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (patients[tiab] OR clinical trial[pt] OR randomized[tiab]) (25 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  24. 24PubMed search (BPC-157): ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (colitis[tiab] OR inflammatory bowel[tiab]) (48 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  25. 25PubMed search (BPC-157): ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (tendon[tiab] OR ligament[tiab] OR muscle[tiab] OR bone[tiab] OR arthritis[tiab]) (58 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  26. 26PubMed search (BPC-157): ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (nerve[tiab] OR neuropath*[tiab] OR spinal[tiab] OR liver[tiab] OR wound[tiab] OR burn[tiab]) (90 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  27. 27PubMed search (BPC-157): ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (57 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  28. 28PubMed search (BPC-157): ("BPC-157"[tiab] OR "BPC 157"[tiab]) AND (human[tiab] OR patient*[tiab] OR volunteer*[tiab]) AND (adverse[tiab] OR safety[tiab] OR "side effects"[tiab]) (19 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  29. 29PubMed search (TB-500): ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) (1199 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  30. 30PubMed search (TB-500): ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (humans[mh] OR patients[tiab]) (678 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  31. 31PubMed search (TB-500): ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (randomized[tiab] OR clinical trial[pt]) (18 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  32. 32PubMed search (TB-500): ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  33. 33PubMed search (TB-500): ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (wound[tiab] OR dermal[tiab] OR skin[tiab] OR hair[tiab]) (212 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  34. 34PubMed search (TB-500): ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (tendon[tiab] OR muscle[tiab] OR cardiac[tiab] OR myocardial[tiab] OR heart[tiab]) (246 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  35. 35PubMed search (TB-500): "TB-500"[tiab] OR TB500[tiab] OR "Ac-LKKTETQ"[tiab] (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  36. 36PubMed search (TB-500): ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab] OR RGN-259[tiab] OR RGN-137[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (61 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  37. 37PubMed search (TB-500): ("RGN-259"[tiab] OR "RGN-137"[tiab] OR "thymosin beta 4"[tiab]) AND (eye[tiab] OR ophthalmic[tiab] OR neurotrophic[tiab] OR cornea*[tiab]) AND (patients[tiab] OR trial[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  38. 38A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials.Archives of internal medicine research · 2026PMID 42787770Accessed 2 Oct 2026
  39. 39Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025PMID 40756949Accessed 2 Oct 2026
  40. 40Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.Journal of chromatography. A · 2012PMID 23084823Accessed 2 Oct 2026
  41. 41Official web pageOfficial web page · web page
  42. 42Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
  43. 43Official web pageOfficial web page · web page

Found an error? Report a correction.